Aliri Launches CyTOF Inflammatory Response Assay as a Powerful Single-Method Alternative to Flow Cytometry and Ligand Binding Assays
R&D Leader to Debut Innovative Method at WRIB Congress
April 7, 2025 – Aliri Bioanalysis, a leading provider of advanced bioanalytical and spatial multi-omics solutions for drug developers, is pleased to announce the launch of Cytometry by Time-Of-Flight (CyTOF), an advanced bioanalysis technique that combines aspects of flow cytometry with mass spectrometry to analyze single cells with high precision.
Commonly applied to immune cell profiling, immunophenotyping, cancer immunotherapy, single-cell functional analysis, and infectious disease research, CyTOF tracks cytokine levels and immune dynamics over time to yield critical data about the mechanism of action, efficacy, safety, and immunomodulatory effects of a drug in real time.
CyTOF overcomes Flow Cytometry limitations with key advantages, including:
- Single-cell resolution with minimal background noise
- Analyzes 40+ markers per cell in a single run
- Consistent signal intensity with no autofluorescence or spectral overlap
- Detailed phenotyping of T cells, B cells, monocytes, NK cells, and their subsets
- No need for PBMC processing
- 72-hours of room temperature stability – no need for expensive cold-chain shipping
Aliri’s next generation Inflammatory Response Assay is more cost efficient and yields deeper insights, with key benefits, including:
- Analyzes 46 markers off the shelf
- Inflammatory data tied directly to cell type – no need for two different methods using Flow Cytometry and kit-based Ligand Binding Assays
- Single blood draw – lower sample volume reduces patient morbidity
- Standard assay can be customized and validated for specific markers and indications
Aliri’s R&D Director, Dr. Corinne Ramos, shares,
“Our skilled team of scientists have over five years of experience using this multi-omics single-cell method on various matrices to support cellular immunophenotyping and inflammatory response monitoring, as it provides sponsors a more detailed understanding of complex immune cell populations including their function and activation.”
Dr. Ramos will be presenting a scientific poster showcasing this advanced assay in action at the 19th annual WRIB conference this week in New Orleans, titled, “Next-Generation Inflammatory Response Assay: Advancing Cytokine and Immune Cell Characterization for Precision Bioanalysis.” Learn more about Aliri’s WRIB activities here.
Aliri Bioanalysis has been a pioneer in the development and application of bioanalytical and spatial multi-omics solutions for over 30 years, and we continue to be at the forefront of innovation today. The launch of CyTOF represents our commitment to providing novel solutions that help our customers to advance their molecule from discovery through clinical development and approval.